Fri, Aug 22, 2014, 9:33 AM EDT - U.S. Markets close in 6 hrs 27 mins

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • pharmatheway pharmatheway Jul 3, 2012 12:55 PM Flag

    Synta on stock run after insider buys

    Tuesday, July 3, 2012, 12:05pm EDT
    Related: Health Care


    Julie M. Donnelly
    Reporter- Boston Business Journal
    Email
    Synta Pharmaceuticals’ (Nasdaq: SNTA) stock rose more than 10 percent Tuesday, and has jumped more than 32 percent since a rash of insider buys June 29. The Lexington, Mass-based biotechnology company has no approved drugs but has six mid-to-late stage clinical trials ongoing for potential cancer therapies.
    Board director Bruce Kovner purchased 910,000 shares on June 29 and currently controls more than 10 percent of the company. Board chairman Keith Gollust purchased 150,000 shares on June 29 and currently controls 2,015,348 shares of the company.
    CEO Safi Bahcall purchased 10,000 shares on June 29 and currently holds 2,343,135 shares of the company. Vice President of Clinical Research Vojo Vukovic purchased 3,000 shares on June 29 and currently holds 25,249 shares of the company.
    Synta’s shares were trading at $6.39 in midday trading Tuesday, up from a previous close of $5.77.

 
SNTA
3.98+0.01(+0.25%)9:33 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.